Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Design of the EXCELLENT Trial

Roncalli, J; Roubille, F; Meyer, N; Pompilio, G; Leroux, L; Henon, P; Trebuchet, G; Criquet, A; de Kalbermatten, M; Saloux, E; Manrique, A; Marie, PY; Bhatt, DL; Solomon, SD; Montalescot, G; Newby, DE; Zannad, F; EXCELLENT Trial Investigators

doi:10.1002/ehf2.15124

Coronary disease & ACS

Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Design of the EXCELLENT Trial

ESC Heart FailPublished 15 Dec 2024Randomised controlled trial

Read the original article ↗PubMed

Cite

Study context

Population: Patients with a large acute myocardial infarction (AMI) and LVEF <50%

Planned comparison: Transendocardial expanded autologous CD34+ cell injection plus standard of care vs standard of care alone
Primary endpoint: Incidence of major adverse cardiac events
Follow-up: 6 months

Methodological detailsdesign paper, multicentre, open-label, phase I/IIb, 3:1 randomisation, Main secondary endpoints: Left ventricular (LV) end systolic volume index and viability of infarcted segments

Design paper
Multicentre
Open-label
Phase I/IIb
3:1 randomisation
Main secondary endpoints: LV end systolic volume index and viability of infarcted segments

No results yet. This paper sets out the design of a trial; its results are to come.

Original publication

Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Design of the EXCELLENT Trial. ESC Heart Fail. Published 15 December 2024. doi:10.1002/ehf2.15124

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →